Predicting response to CGRP(-receptor) monoclonal antibodies – learnings from super- and non-responders

In a retrospective cohort study, patients with migraine (n=260) were treated with preventative CGRP(-receptor) monoclonal antibodies. 11% and 10% were identified as super responders and non-responders respectively.
Those identified as super responders presented with more typical migraine characteristics such as vomiting, unilateral localization, pulsating character, photophobia, and nausea. Super responders responded better to triptans than non-responders (P=0.01).
The authors concluded that there are several clinical parameters that differ between individuals who are CGRP(-receptor) monoclonal antibody non-responders and super responders. Evaluation of clinical presentation prior to treatment might help in predicting likelihood of treatment success.